{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:13:58Z","timestamp":1760552038931,"version":"3.41.2"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Daprodustat is an oral small molecule hypoxia\u2010inducible factor (HIF) prolyl hydroxylase inhibitor (PHI) approved in Japan and the United States for the treatment of anemia associated with chronic kidney disease. This phase 1, nonrandomized, 2\u2010period, crossover study in 6 healthy men characterized and quantified the metabolites generated after a microtracer IV infusion of 50\u2009\u03bcg (125 nCi) [<jats:sup>14<\/jats:sup>C]\u2010daprodustat administered concomitantly with a nonradiolabeled therapeutic dose of a 6\u2010mg daprodustat tablet, followed by a single oral solution dose of 25\u2009mg (62.5\u2009\u03bcCi) [<jats:sup>14<\/jats:sup>C]\u2010daprodustat. High\u2010performance liquid chromatography (HPLC) coupled with radioactivity detection (TopCount or AMS) and HPLC\u2010tandem mass spectrometry (HPLC\u2010MS<jats:sup>n<\/jats:sup>) were used for quantitative measurement and structural identification of radioactive metabolites in plasma, urine, feces, and bile. Following oral administration of [<jats:sup>14<\/jats:sup>C]\u2010daprodustat, unchanged daprodustat was the principal circulating drug\u2010related component, accounting for 40% of plasma radioactivity. Predominant oxidative metabolites M2, M3, M4, and M13 individually represented 6\u20138% of the plasma radioactivity and together accounted for the majority of radioactivity in urine and feces (53% in both matrices; 12% and 41% of dose, respectively). Unchanged daprodustat was not detected in urine and was only 0.7% of total radioactivity in feces (&lt;0.5% of dose), with the remainder of the dose accounted for by oxidative metabolites. The radio\u2010metabolic profile of duodenal bile following IV infusion of [<jats:sup>14<\/jats:sup>C]\u2010daprodustat was similar to that observed in feces after oral administration. The data suggested that oral daprodustat was extensively absorbed, cleared exclusively by oxidative metabolism, and eliminated via hepatobiliary (primary) and urinary (secondary) excretion.<\/jats:p>","DOI":"10.1002\/prp2.1145","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T05:58:40Z","timestamp":1698386320000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Investigation of the human metabolism and disposition of the prolyl hydrolase inhibitor daprodustat using IV microtracer with Entero\u2010Test bile string"],"prefix":"10.1002","volume":"11","author":[{"given":"Guoying","family":"Tai","sequence":"first","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics GSK  Collegeville Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangming","family":"Xia","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics GSK  Collegeville Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Chen","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics GSK  Collegeville Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Pereira","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics GSK, Stevenage  Hertfordshire UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Pirhalla","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics GSK  Collegeville Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiusheng","family":"Miao","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics GSK  Collegeville Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme","family":"Young","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics GSK, Ware  Hertfordshire UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Beaumont","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics GSK, Stevenage  Hertfordshire UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6389-7918","authenticated-orcid":false,"given":"Liangfu","family":"Chen","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics GSK  Collegeville Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011111078"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907845"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065485"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.11.021"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy013"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1029"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy014"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015030241"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.07.019"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242503"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010010116"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.12.011"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2017.05.004"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz013"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03956.x"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/js970486q"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033822200063529"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nimb.2005.06.168"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15537"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623319880445"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.83"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015888813741"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.035089"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.616"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.058420"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.122.000955"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000595"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2015.11.057"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.1145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T03:57:46Z","timestamp":1703995066000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.1145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/prp2.1145"],"URL":"https:\/\/doi.org\/10.1002\/prp2.1145","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"type":"print","value":"2052-1707"},{"type":"electronic","value":"2052-1707"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"2023-09-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1145"}}